Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Engraftment in IBS
NCT02847481Phase 1Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2016
- Primary completion
- Aug 2018
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of allogeneic fecal microbiota in Irritable bowel syndrome with diarrhea (IBS-D) (4 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Stable engraftment of donor microbiota at 10 weeks. Started May 2016; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT02847481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847481.